An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand.
Fas ligand (FasL), either in the membrane bound form or soluble form, has cytotoxic activity against Fas-expressing cells. We report a case of nasal lymphoma accompanied by liver damage and pancytopenia. The serum level of soluble FasL (sFasL) was very high on admission, but rapidly decreased to normal levels after chemotherapy for lymphoma. Liver damage and pancytopenia also improved with the decrease in serum sFasL. Since Fas is expressed on both hepatocytes and haemopoietic cells, these facts suggest that FasL was expressed on lymphoma cells and directly associated with pathogenesis of liver damage and pancytopenia through its cytotoxic activity.
Sato
K
K
Third Department of Internal Medicine, National Defence Medical College, Saitami, Japan.
Kimura
F
F
Nakamura
Y
Y
Murakami
H
H
Yoshida
M
M
Tanaka
M
M
Nagata
S
S
Kanatani
Y
Y
Wakimoto
N
N
Nagata
N
N
Motoyoshi
K
K
D004797:Enzyme-Linked Immunosorbent Assay; D053222:Fas Ligand Protein; D006801:Humans; D007694:Killer Cells, Natural / Q000378:metabolism*; D007958:Leukocyte Count; D008107:Liver Diseases / Q000378:metabolism; D008223:Lymphoma / Q000378:metabolism*; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism*; D008875:Middle Aged; D009669:Nose Neoplasms / Q000378:metabolism*
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins